

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for December 2025

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Apotex Inc.	Apo-Cladribine	Mavenclad	CLADRIBINE	10 mg	tablet	02553295
Sanis Health Inc.	Metformin ER	Glumetza	METFORMIN HCl	1000 mg	ER tablet	02558793
Sanis Health Inc.	Metformin ER	Glumetza	METFORMIN HCL	500 mg	ER tablet	02558785
Pharmascience Inc.	Pms-Methotrexate Tablets	Methotrexate	METHOTREXATE	10 mg	tablet	02561956
Jamp Pharma Corporation	Jamp Nintedanib	Ofev	NINTEDANIB ESILATE	100 mg	capsules	02550849

Jamp Pharma Corporation	Jamp Nintedanib	Ofev	NINTEDANIB ESILATE	150 mg	capsules	02540762
Sivem Pharmaceuticals	Valacyclovir	Valtrex	VALACYCLOVIR HCL	1000 mg	tablet	02553511
Pharmaris Canada Inc.	PRZ-Amlodipine	Norvasc	AMLODIPINE	2.5mg	tablet	02522500
Zydus Lifesciences Limited	ZDS-Liothyronine	Cytomel	LIOTHYRONINE SODIUM	5 mcg	tablet	02561298
Zydus Lifesciences Limited	ZDS-Liothyronine	Cytomel	LIOTHYRONINE SODIUM	25 mcg	tablet	02561301